This patent contains claims covering CRx-191, the company’s lead topical dermatology product candidate, and other product candidates, and will expire in 2022, unless extended.
Alexis Borisy, president and CEO of CombinatoRx, said: “This is a significant addition to our growing intellectual property estate, and we anticipate the issuance of additional patents covering CombinatoRx product candidates in the near future.”